After the GLP-1 boom: the race for next-generation obesity drugs intensifies

In just a few years, GLP-1 has transformed the obesity treatment market. Now, interest is growing in pills, new mechanisms of action and treatments that can do more than simply reduce weight

You need to be a subscriber to read this article.
Click here to find out more.

Biotech company Pila Pharma, founded by former Novo Nordisk researcher Dorte X. Gram, recently received regulatory approval to conduct a 12-week clinical trial with the drug candidate XEN-D0501 in people with obesity.

After the GLP-1 boom: the race for next-generation obesity drugs intensifies

The trial will investigate safety, tolerability, pharmacokinetics and efficacy at higher doses than previously studied, marking an important next step in the development of a potential new oral treatment for obesity. The trial is now ongoing.

XEN-D0501 differs from the dominant GLP-1 treatments by being a TRPV1 antagonist. Rather than targeting hormones such as GLP-1 and amylin, it acts on the TRPV1 receptor, which is involved in pain and inflammation.

In the trial, up to 46 participants will be treated, with the dose gradually increasing from 4 mg twice daily to a maximum of 16 mg twice daily, provided the individual participant tolerates the dose. 

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.

You may also like